29 April 2024
Futura Medical
plc
("Futura" or the
"Company")
Directors' / PDMR Dealing and
Grant of Options
Futura Medical plc (AIM:
FUM), the consumer healthcare company
behind Eroxon, that specialises in the development
and global commercialisation of innovative and clinically
proven sexual health products, announces that it has granted
options over a total of 2,176,000 ordinary shares of 0.2p each in
the Company ("Ordinary Shares") to employees and Directors, of
which 905,000 options were granted to Directors and PDMRs as
detailed below. The options are part of annual awards made by
Futura in accordance with existing share schemes.
|
Director
|
Number
of options
granted
|
Exercise
price
|
Exercise
period
|
Total number
of options
held following
notification
|
Total number
of Ordinary
Shares held
|
|
|
|
|
|
|
|
|
J H
Barder
|
345,000
|
35.50p
|
1 April
2027 - 31 Mar 2034
|
3,960,927
|
1,420,972
|
|
|
|
|
|
|
|
|
A
Hildreth
|
280,000
|
35.50p
|
1 April
2027 - 31 Mar 2034
|
3,320,082
|
142,857
|
|
|
|
|
|
|
|
|
K W
James
|
280,000
|
35.50p
|
1 April
2027 - 31 Mar 2034
|
3,655,953
|
299,581
|
Of the total 2,176,000 options,
1,611,000 were granted under the Futura Medical plc Enterprise
Management Incentive Scheme, and 565,000 were granted under the
unapproved scheme.
Vesting is subject to the
achievement of a performance-related milestone and that the
Director/PDMR/employee remains employed with the Company as at the
date of exercise. Further disclosures are contained in the
tables below.
ENDS
Contacts:
|
Futura Medical plc
|
James Barder
Chief Executive Officer
Angela Hildreth
Finance Director and COO
|
investor.relations@futuramedical.com
+44 (0)1483 685 670
www.futuramedical.com
|
|
Liberum
Nominated Adviser
and Broker
|
Phil Walker
Richard Lindley
Nikhil Varghese
|
+44 (0)20 3100 2000
|
|
|
|
|
|
Stifel Nicolaus Europe Limited
Joint Broker
|
Alan Selby
Ben Maddison
|
+44 (0)207 710 7600
|
|
|
|
|
|
Alma Strategic Communications
|
Rebecca Sanders-Hewett
Sam Modlin
Will Ellis Hancock
|
+44 (0)20 3405 0205
futura@almastrategic.com
|
|
|
|
|
Notes to Editors:
Futura Medical plc (AIM: FUM) is the
developer of innovative sexual health products, including lead
product Eroxon. Our core strength lies in our research, development
and commercialisation of topically delivered gel formulations in
sexual health products.
Eroxon, Futura's clinically proven
lead product, has been developed for the treatment of Erectile
Dysfunction ("ED"). The highly differentiated product,
which is the only topical gel treatment for ED available over the
counter and helps men get an erection in ten
minutes, addresses significant unmet needs in the ED
market.
ED impacts 1 in 5 men globally
across all adult age brackets, with approximately half of all men
over 40 experiencing ED and 25% of all new diagnoses being in men
under 40.
Futura has distribution partners in
place in a number of major consumer markets including Haleon in the
US, the largest market for ED in the world, and Cooper Consumer
Health in Europe. Eroxon has been nominated for a number of
healthcare industry awards and has won two to-date.
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name
|
James Barder
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Executive Officer
|
|
b)
|
Initial
notification/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Futura Medical plc
|
|
b)
|
LEI
|
21380053QLT46UNV2303
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Options over Ordinary Shares of 0.2
pence each
GB0033278473
|
|
b)
|
Nature of the transaction
|
Grant of options over Ordinary
Shares
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
-
|
345,000
|
|
|
d)
|
Aggregated information
- Aggregated
volume
-
Price
|
N/A single transaction
|
|
e)
|
Date of the transaction
|
26 April 2024
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name
|
Angela Hildreth
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Finance Director and
Chief Operating Officer
|
|
b)
|
Initial
notification/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Futura Medical plc
|
|
b)
|
LEI
|
21380053QLT46UNV2303
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Options over Ordinary Shares of 0.2
pence each
GB0033278473
|
|
b)
|
Nature of the transaction
|
Grant of options over Ordinary
Shares
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
-
|
280,000
|
|
|
d)
|
Aggregated information
- Aggregated
volume
-
Price
|
N/A single transaction
|
|
e)
|
Date of the transaction
|
26 April 2024
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name
|
Ken James
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Executive Director
and Head of R&D
|
|
b)
|
Initial
notification/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Futura Medical plc
|
|
b)
|
LEI
|
21380053QLT46UNV2303
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Options over Ordinary Shares of 0.2
pence each
GB0033278473
|
|
b)
|
Nature of the transaction
|
Grant of options over Ordinary
Shares
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
-
|
280,000
|
|
|
d)
|
Aggregated information
- Aggregated
volume
-
Price
|
N/A single transaction
|
|
e)
|
Date of the transaction
|
26 April 2024
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|